Swiss drug-maker Novartis has entered collaboration and licensing agreements with Intellia Therapeutics to develop new medicines using CRISPR genome editing technology and Caribou Biosciences for drug discovery tools.
A new technique has been developed utilizing nanotechnology to detect disease biomarkers in the form of nucleic acids.The proof-of-concept study came from a team of researchers at Wake Forest Baptist Medical Center
Hilleman Laboratories, a joint venture of Merck and Wellcome Trust, has signed a memorandum of understanding (MoU) with Bangladesh-based icddr,b and Incepta Vaccine to develop an oral cholera vaccine.
Japan-based Takeda Pharmaceutical has signed an alliance agreement with GE Healthcare for research and development of hepatic fibrosis.
Scientists at the UK's Medical Research Council (MRC) have created the world's first enzymes made from artificial genetic material, which are capable of triggering chemical reactions in the laboratory.
Amgen has received approval for review from US Food and Drug Administration (FDA) for its evolocumab to treat high cholesterol.
exscientia Ltd. the polypharmacology driven drug discovery company announced today that they have signed an agreement with Sunovion Pharmaceuticals Inc. to collaborate on the discovery and optimisation of novel medicines for psychiatric disorders.